Satellos Bioscience Inc.
MSCL.TO
TSX
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -387.01% | -9.94% | |||
| Gross Profit | 387.01% | 9.94% | |||
| SG&A Expenses | 11.16% | 2.07% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 28.18% | -6.30% | |||
| Operating Income | -28.18% | 6.30% | |||
| Income Before Tax | -24.87% | -4.05% | |||
| Income Tax Expenses | 205.26% | -40.63% | |||
| Earnings from Continuing Operations | -25.46% | -3.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -25.46% | -3.80% | |||
| EBIT | -28.18% | 6.30% | |||
| EBITDA | -28.24% | 6.35% | |||
| EPS Basic | -13.13% | -6.21% | |||
| Normalized Basic EPS | -12.62% | -6.47% | |||
| EPS Diluted | -13.13% | -6.21% | |||
| Normalized Diluted EPS | -12.62% | -6.47% | |||
| Average Basic Shares Outstanding | 10.91% | -2.27% | |||
| Average Diluted Shares Outstanding | 10.91% | -2.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||